Home » Newsletters » BioWorld Science

BioWorld Science

April 17, 2014

View Archived Issues

Phase I results for MRX-34, a first-in-class liposome formulated miR-34 mimic

Sigma-Tau describes novel HSP 90 inhibitor

Interstitial deletion of 8p23.1 indicates a new causative gene for heterotaxy

Neuregulin-1 expression correlates with sensitivity to GDC-0032 PI3K inhibitor

Researchers present a novel method to predict the risk of rejection after heart transplant

Sym-013 augments response to lung and head and neck cancer tumors

Multiple studies examine treatment of HCV infection with veruprevir/ritonavir/ombitasvir combination

Karyopharm initiates phase I trial of selinexor and decitabine in AML

Kyowa Hakko Kirin begins phase III trials of benralizumab in Japan and South Korea

Prevention of PGE2-induced bladder overactivity by TRPM8 blocker DFL-23448

LDC and Daiichi Sankyo form early drug discovery alliance

OxThera receives financing to continue key clinical programs

SOM Biotech and Vall d'Hebron Research Institute team up to develop transthyretin amyloidosis drug

Dosing begins in phase I/II trial of APR-246 in ovarian cancer

Phase III trial of Baxter's BAX-111 achieves primary endpoint

Suglat tablets launched in Japan for type 2 diabetes

Iconic Therapeutics raises funding for development of AMD therapy

Epirus Biopharmaceuticals to merge with Zalicus

New anti-CD3 antibodies disclosed by Regeneron Pharmaceuticals

Researchers at the University of Washington design novel vaccines for viral infections

Bristol-Myers Squibb presents new XIAP inhibitors for cancer

Cleveland BioLabs announces results of CBL-0102 phase I cancer trial

Chugai to launch trastuzumab emtansine in Japan

Merck KGaA synthesizes novel FAS inhibitors

Effimune reports advances in the development of a new class of monoclonal antibodies

ViiV Healthcare launches dolutegravir in Japan

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Jan 16, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Jan. 16, 2026.
Abbvie snags PD-1/VEGF bispecific in potential $5B Remegen deal
BioWorld
With rumors regarding a couple of potential mega-mergers making the rounds, the week of the annual J.P. Morgan Healthcare Conference kicked off with the official...
Cell/gene therapy sector now sustainable; China competition mounting
BioWorld
There was an upbeat message for cell and gene therapy companies in the 2026 industry update presented as the J.P. Morgan Healthcare Conference opened on Monday,...
JPM 2026: Year kicks off with biopharma Q4 revenue and guidance
BioWorld
It was a battle of the companies with drugs for transthyretin-mediated amyloidosis on the first day of the J.P. Morgan 2026 Healthcare Conference with Alnylam...